Katherine G. Moss

4.5k total citations · 1 hit paper
17 papers, 1.9k citations indexed

About

Katherine G. Moss is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Katherine G. Moss has authored 17 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Katherine G. Moss's work include Melanoma and MAPK Pathways (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and Virus-based gene therapy research (3 papers). Katherine G. Moss is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and Virus-based gene therapy research (3 papers). Katherine G. Moss collaborates with scholars based in United States and Switzerland. Katherine G. Moss's co-authors include Elisabeth A. Minthorn, Sylvie Laquerre, Jingsong Yang, Alexander Laird, Dirk B. Mendel, Julie M. Cherrington, Maureen R. Bleam, David Sutton, Guangmin Li and Kelly E. Fisher and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Katherine G. Moss

17 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

2013 364 citations Charity Atkins, Qi Liu et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katherine G. Moss United States	15	1.2k	666	423	228	214	17	1.9k
Elisabeth A. Minthorn United States	15	953 0.8×	341 0.5×	449 1.1×	313 1.4×	228 1.1×	23	1.7k
Annalisa Petrelli Italy	19	1.4k 1.2×	490 0.7×	322 0.8×	115 0.5×	146 0.7×	26	2.1k
Jessie Villanueva United States	18	1.6k 1.3×	799 1.2×	314 0.7×	88 0.4×	139 0.6×	30	2.1k
Matthew R. Janes United States	15	2.2k 1.8×	594 0.9×	160 0.4×	132 0.6×	251 1.2×	26	2.7k
Alastair J. King United States	18	1.6k 1.3×	659 1.0×	289 0.7×	50 0.2×	134 0.6×	28	2.0k
Inna V. Fedorenko United States	16	1.3k 1.1×	809 1.2×	199 0.5×	68 0.3×	112 0.5×	27	1.6k
David A. Proia United States	30	1.9k 1.5×	945 1.4×	275 0.7×	125 0.5×	376 1.8×	57	2.6k
Bingbing Dai United States	28	1.6k 1.3×	590 0.9×	210 0.5×	205 0.9×	197 0.9×	48	2.3k
Xuewu Zhang China	11	1.1k 0.9×	879 1.3×	146 0.3×	160 0.7×	434 2.0×	29	1.8k
Josef Brueggen Switzerland	10	1.8k 1.5×	633 1.0×	125 0.3×	123 0.5×	348 1.6×	14	2.4k

Countries citing papers authored by Katherine G. Moss

Since Specialization

Citations

This map shows the geographic impact of Katherine G. Moss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine G. Moss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine G. Moss more than expected).

Fields of papers citing papers by Katherine G. Moss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine G. Moss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine G. Moss. The network helps show where Katherine G. Moss may publish in the future.

Co-authorship network of co-authors of Katherine G. Moss

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine G. Moss. A scholar is included among the top collaborators of Katherine G. Moss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine G. Moss. Katherine G. Moss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Atkins, Charity, Qi Liu, Elisabeth A. Minthorn, et al.. (2013). Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Research. 73(6). 1993–2002. 364 indexed citations breakdown →

King, Alastair J., Marc R. Arnone, Maureen R. Bleam, et al.. (2013). Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE. 8(7). e67583–e67583. 163 indexed citations

Rheault, Tara, John Stellwagen, George M. Adjabeng, et al.. (2013). Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Medicinal Chemistry Letters. 4(3). 358–362. 175 indexed citations

Gilmartin, Aidan G., Maureen R. Bleam, Arthur Groy, et al.. (2011). GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clinical Cancer Research. 17(5). 989–1000. 459 indexed citations

Hardwicke, Mary Ann, Catherine A. Oleykowski, Ramona Plant, et al.. (2009). GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Molecular Cancer Therapeutics. 8(7). 1808–1817. 89 indexed citations

Laquerre, Sylvie, Marc R. Arnone, Katherine G. Moss, et al.. (2009). Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Molecular Cancer Therapeutics. 8(12_Supplement). B88–B88. 45 indexed citations

Gilmartin, Aidan G., David Sutton, Katherine G. Moss, et al.. (2008). 567 POSTER GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models. European Journal of Cancer Supplements. 6(12). 178–178. 2 indexed citations

Potapova, Olga, Alexander Laird, Michelle Nannini, et al.. (2006). Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Molecular Cancer Therapeutics. 5(5). 1280–1289. 90 indexed citations

Spencer, Jeffrey R., Martin Sendzik, Jason Oeh, et al.. (2006). Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo. Bioorganic & Medicinal Chemistry Letters. 16(18). 4884–4888. 15 indexed citations

10.

Moss, Katherine G., Guy C. Toner, Julie M. Cherrington, Dirk B. Mendel, & Alexander Laird. (2003). Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans. Journal of Pharmacology and Experimental Therapeutics. 307(2). 476–480. 62 indexed citations

11.

Sun, Li, Deborah Moshinsky, Hui Chen, et al.. (2003). A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability. Journal of Pharmacology and Experimental Therapeutics. 306(3). 838–845. 32 indexed citations

12.

Laird, Alexander, Guangmin Li, Katherine G. Moss, et al.. (2003). Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.. PubMed. 2(5). 461–9. 92 indexed citations

13.

Laird, Alexander, James G. Christensen, Guangmin Li, et al.. (2002). SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. The FASEB Journal. 16(7). 681–690. 116 indexed citations

14.

Austin, Timothy W., Katherine G. Moss, Franck Morel, & Ivan Plavec. (2001). An Improved Vector for High-Level, Consistent Retroviral Transgene Expression in Human Thymocytes after Competitive Reconstitution from Transduced Peripheral Blood Stem Cells. Human Gene Therapy. 12(10). 1239–1249. 3 indexed citations

15.

Bonyhadi, Mark, Katherine G. Moss, Ivan Plavec, et al.. (1997). RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. Journal of Virology. 71(6). 4707–4716. 84 indexed citations

16.

Plavec, Ivan, et al.. (1996). Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic progenitor cells.. PubMed. 3(8). 717–24. 25 indexed citations

17.

Lee, Richard, et al.. (1996). Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood. 87(4). 1261–1271. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact